Timothy Babinchak
Overview
Explore the profile of Timothy Babinchak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
563
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stein G, Babinchak T
Diagn Microbiol Infect Dis
. 2013 Jan;
75(4):331-6.
PMID: 23357291
Tigecycline is a broad-spectrum antibiotic with activity against difficult-to-treat pathogens such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus spp., Acinetobacter baumannii, and Gram-negative bacterial strains that produce extended-spectrum β-lactamases. Minimal organ...
2.
Matthews P, Alpert M, Rahav G, Rill D, Zito E, Gardiner D, et al.
BMC Infect Dis
. 2012 Nov;
12:297.
PMID: 23145952
Background: Complicated skin and skin structure infections (cSSSIs) frequently result in hospitalization with significant morbidity and mortality. Methods: In this phase 3b/4 parallel, randomized, open-label, comparative study, 531 subjects with...
3.
Ramirez J, Cooper A, Wiemken T, Gardiner D, Babinchak T
BMC Infect Dis
. 2012 Jul;
12:159.
PMID: 22812672
Background: Switch therapy is a management approach combining early discontinuation of intravenous (IV) antibiotics, switch to oral antibiotics, and early hospital discharge. This analysis compares switch therapy using tigecycline versus...
4.
Metersky M, Masterton R, Lode H, File Jr T, Babinchak T
Int J Infect Dis
. 2012 Mar;
16(5):e321-31.
PMID: 22387143
Post-influenza bacterial pneumonia is a major cause of morbidity and mortality associated with both seasonal and pandemic influenza virus illness. However, despite much interest in influenza and its complications in...
5.
McGovern P, Babinchak T, Quintana A
Antimicrob Agents Chemother
. 2011 Sep;
55(10):4941.
PMID: 21921119
No abstract available.
6.
Gardiner D, Dukart G, Cooper A, Babinchak T
Clin Infect Dis
. 2009 Dec;
50(2):229-38.
PMID: 20025527
Background: Tigecycline is effective in the treatment of complicated skin/skin-structure infection (cSSSI), complicated intraabdominal infection (cIAI), and community-acquired bacterial pneumonia (CAP), but its efficacy in subjects with secondary bacteremia is...
7.
Passarell J, Ludwig E, Liolios K, Meagher A, Grasela T, Babinchak T, et al.
Diagn Microbiol Infect Dis
. 2009 Sep;
65(2):123-9.
PMID: 19748422
Tigecycline exposure (area under the concentration-time curve [AUC((0-infinity))] and maximum serum concentration [C(max)]) and first occurrence of nausea and vomiting were evaluated in 136 healthy subjects after 12.5- to 300-mg...
8.
Ambrose P, Meagher A, Passarell J, Van Wart S, Cirincione B, Rubino C, et al.
Diagn Microbiol Infect Dis
. 2008 Dec;
63(1):38-42.
PMID: 19073300
Potential tigecycline-Enterobacteriaceae susceptibility breakpoints were evaluated using 2 approaches, which differed in the nature of the probabilities assessed by MIC value. Using a previously derived tigecycline population pharmacokinetic model and...
9.
McAleese F, Murphy E, Babinchak T, Singh G, Said-Salim B, Kreiswirth B, et al.
Antimicrob Agents Chemother
. 2005 Oct;
49(11):4521-9.
PMID: 16251291
A retrospective study was performed to identify methicillin-resistant Staphylococcus aureus (MRSA) isolates obtained from patients enrolled in phase 3 clinical trials for tigecycline that were genotypically similar to known community-associated...
10.
Oliva M, Rekha A, Yellin A, Pasternak J, Campos M, Rose G, et al.
BMC Infect Dis
. 2005 Oct;
5:88.
PMID: 16236177
Background: Complicated intra-abdominal infections (cIAI) remain challenging to treat because of their polymicrobial etiology including multi-drug resistant bacteria. The efficacy and safety of tigecycline, an expanded broad-spectrum glycylcycline antibiotic, was...